Management of Propofol Infusion Syndrome in Sedated Patients

Diagnostic Considerations

Involuntary movements in a sedated patient on propofol may represent early neuromuscular manifestations of Propofol Infusion Syndrome (PRIS), a potentially fatal complication, and immediate assessment is crucial 1
Obtain urgent laboratory studies to evaluate for PRIS, including arterial blood gas, serum triglycerides, serum potassium, and renal function tests, to assess the severity of the condition 1
Monitor continuously for cardiac manifestations, including bradycardia, arrhythmias, hypotension, and signs of cardiac failure, as these can be indicative of PRIS 1

Evaluate the patient's specific PRIS risk factors, including current infusion rate (>70 μg/kg/min is high risk) and acute neurological illness or inflammatory conditions, to determine the likelihood of developing PRIS 1
Consider the duration of propofol infusion, as >48 hours significantly increases the risk of PRIS, and adjust the treatment plan accordingly 1

Transition immediately to dexmedetomidine-based sedation as the preferred alternative in cardiovascular patients, with a loading dose of 1 μg/kg over 10 minutes and maintenance infusion of 0.2-0.7 μg/kg/hr, to minimize the risk of PRIS 1, 2
If dexmedetomidine is contraindicated, consider midazolam with a loading dose of 0.01-0.05 mg/kg and maintenance of 0.02-0.1 mg/kg/hr, but be aware of the potential for delirium and respiratory depression 4
Maintain analgesic coverage throughout the transition with fentanyl infusion at 25-300 μg/hr (0.5-5 μg/kg/hr), as propofol has no analgesic properties 2, 5

Rule out other causes of involuntary movements, such as shivering, paradoxical agitation, seizure activity, and delirium with motor manifestations, to ensure accurate diagnosis and treatment 3, 4, 6
Consider meperidine 12.5-50 mg or magnesium sulfate 2-4 g bolus, then 1 g/hr infusion, for shivering, and low-dose haloperidol or levomepromazine for delirium, to manage symptoms effectively 3, 5, 6

If PRIS is confirmed or highly suspected, discontinue propofol immediately and provide aggressive supportive care, including hemodynamic support, correction of metabolic acidosis, and renal replacement therapy, to improve patient outcomes 1
Consider extracorporeal membrane oxygenation (ECMO) for refractory cardiac failure, and be aware that mortality approaches 33% even with aggressive treatment, to guide treatment decisions 1